Article
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2008
Costa Daniel B, Nguyen Kim-Son H, Cho Byoung C, Sequist Lecia V, Jackman David M, Riely Gregory J, Yeap Beow Y, Halmos Balázs, Kim Joo H, Jänne Pasi A, Huberman Mark S, Pao William, Tenen Daniel G, Kobayashi Susumu
Abstract excerpt
PURPOSE: Most lung cancers with activating epidermal growth factor receptor (EGFR) mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) invariably ensues. The T790M mutation occurs in 50% and MET amplification in 20% of TKI-resistant tumors. Other secondary...
Topics
- Adenocarcinoma
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Gefitinib
- Humans
- Lung Neoplasms